Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2006 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Hoffmann-La Roche
Sanquin Research & Blood Bank Divisions
Information provided by:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier:
NCT00120419
First received: July 11, 2005
Last updated: July 21, 2009
Last verified: January 2006

July 11, 2005
July 21, 2009
April 2005
Not Provided
Change over time (baseline - week 48) in CD4+ cell counts in peripheral blood and peripheral blood lymphocyte activation markers.
  • *Change over time (baseline – week 48) in CD4+ cell counts in peripheral blood
  • *Peripheral blood lymphocyte activation markers.
Complete list of historical versions of study NCT00120419 on ClinicalTrials.gov Archive Site
* Change over time (baseline - week 48) in plasma HIV-1 RNA, time to reach an indication to start antiretroviral treatment and safety parameters.
  • * Change over time (baseline – week 48) in plasma HIV-1 RNA
  • * Time to reach an indication to start antiretroviral treatment
  • * Safety parameters.
Not Provided
Not Provided
 
Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)
Not Provided

The purpose of the study is to evaluate whether mycophenolate mofetil (MMF) can treat the chronic hyperactivation of the immune system and (partly) prevent the decrease of the CD4+ T-cell count in chronically HIV-1 infected patients who are not treated with antiretroviral therapy (ART). The researchers also want to know what the effect is of treatment with MMF on plasma HIV-1 RNA; progression of disease (occurrence of AIDS defining events or reaching the indication to start ART); and the safety of treatment with MMF in this patient group.

*Background: During chronic HIV-1 infection the immune system is chronically hyperactivated. This hyperactivation is considered as the main cause of CD4+ T-cell loss. Furthermore, HIV replicates most efficiently in activated CD4+ T-cells. In this study we try to inhibit the activation of the immune system with mycophenolate mofetil (MMF). Previous studies in which HIV-1 infected patients have been treated with MMF in addition to antiretroviral treatment (ART) have not shown any additional effect, compared to ART alone. In this study MMF will be used without antiretroviral medication.

*Objectives: Primary objective of the study is the evaluation of the effect of MMF on the chronic hyperactivation of the immune system and the decrease of the CD4+ T-cell count in chronically HIV-1 infected patients who are not treated with antiretroviral therapy (ART). Secondary objectives include the evaluation of the effect of MMF on plasma HIV-1 RNA; progression of disease/ reaching of indication to start ART; and the safety of treatment with MMF in this patient group.

*Study Design: This is a multi center, randomized, open-label study, in which patients will be randomized to treatment with mycophenolate mofetil (MMF) 500 mg BID during 48 weeks versus no treatment. In a subgroup of 20 patients ("immunology group", the first 20 patients in the AMC hospital, Amsterdam, the Netherlands) a number of additional immunological measurements will be performed.

The study duration is 60 weeks (48 weeks of treatments with 1 additional visit 12 weeks after cessation of treatment).

*Study Population: Potential participants are adult chronically HIV-1 infected patients, who have never been treated with ART and who according to the present criteria do not need to be treated. CD4+ T lymphocyte count has to be > 250 and <= 450 * 106/L, plasma HIV-1 RNA (viral load) < 10.000 copies/ mL.

*Intervention: Patients will be randomized (1:1) to mycofenolate mofetil (MMF) 500 mg BID versus no treatment.

*Endpoints: Primary endpoints are change over time (baseline - week 48) in CD4+ T cell count and peripheral blood lymphocyte (PBMC) activation markers.

Secondary endpoints are changes over time (baseline - week 48) in plasma HIV-1 RNA, time to reach indication to start ART (separated in three groups: 1. two consecutive measurements of CD4+ T cell count below 250 * 106 cells/ L with at least 4 weeks interval; 2. the occurrence of a CDC class B or C event; 3. any other reason); safety data.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
HIV Infection
Drug: mycophenol mofetil (MMF, Cellcept®) 500 mg BID
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
90
Not Provided
Not Provided

Inclusion Criteria:

  • Patient is ≥ 18 years of age;
  • Patient has a proven HIV-1 infection (with antibodies against HIV-1 and a detectable plasma HIV-1 RNA measured for the first time at least 6 months prior to inclusion);
  • Patient is HIV-1 treatment naïve;
  • CD4+ T lymphocyte count > 250 and <= 450 * 106/L;
  • No signs or history of AIDS defining events;
  • No use of other medications that might possibly influence the effects of MMF;
  • Male; or female sex and willingness to practice effective contraception during the study.

Exclusion Criteria:

  • Plasma HIV-1 RNA < 10.000 copies/ mL;
  • Autoimmune disease;
  • Active hepatitis B or C virus infection;
  • Other chronic diseases;
  • Recent infectious disease other than HIV-1;
  • Treatment with immunomodulatory or anti-inflammatory medication in the past 6 months;
  • For female patients: pregnancy and lactation;
  • Any other condition, illness or use of medication which according to the investigator is not compatible with the use of the study medication or which could interfere with the evaluations required by the study.
Both
18 Years and older
No
Contact: Joost N Vermeulen, MD +31 20 5668992 j.n.vermeulen@amc.uva.nl
Contact: Jan M Prins, MD PhD +31 20 5669111 j.m.prins@amc.uva.nl
Netherlands
 
NCT00120419
MAN2-study
Yes
Not Provided
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Hoffmann-La Roche
  • Sanquin Research & Blood Bank Divisions
Principal Investigator: Jan M Prins, MD PhD Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, the Netherlands
Principal Investigator: Kees Brinkman, MD PhD department of internal medicine, OLVG hospital, Amsterdam, the Netherlands
Principal Investigator: Robin Soetekouw, MD department of internal medicine, Kennemer Gasthuis, Haarlem, the Netherlands
Principal Investigator: Robert Kauffmann, MD PhD Department of Internal Medicine, HAGA hospital, location Leyenburg Hospital, The Hague, The Netherlands
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
January 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP